West Pharmaceutical Services (WST) to Release Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $1.83 per share and revenue of $795.6980 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

West Pharmaceutical Services Stock Up 2.7%

West Pharmaceutical Services stock opened at $237.09 on Thursday. The company has a market capitalization of $17.06 billion, a P/E ratio of 35.12, a PEG ratio of 3.18 and a beta of 1.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87. West Pharmaceutical Services has a fifty-two week low of $187.43 and a fifty-two week high of $335.64. The stock has a 50-day simple moving average of $265.64 and a 200-day simple moving average of $261.58.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th were paid a $0.22 dividend. The ex-dividend date was Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. West Pharmaceutical Services’s payout ratio is currently 13.04%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. KeyCorp raised their target price on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, October 24th. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, January 9th. UBS Group lifted their price objective on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, October 24th. TD Cowen assumed coverage on shares of West Pharmaceutical Services in a report on Wednesday, October 29th. They issued a “buy” rating for the company. Finally, Evercore ISI cut their price target on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, West Pharmaceutical Services has an average rating of “Buy” and a consensus target price of $328.00.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of hedge funds and other institutional investors have recently modified their holdings of WST. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new position in West Pharmaceutical Services during the second quarter worth $47,000. State of Wyoming purchased a new stake in West Pharmaceutical Services during the second quarter worth $49,000. Darwin Wealth Management LLC purchased a new stake in West Pharmaceutical Services during the second quarter worth $75,000. Finally, EverSource Wealth Advisors LLC grew its holdings in West Pharmaceutical Services by 78.2% in the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 197 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.